View
772
Download
0
Embed Size (px)
Citation preview
1 Redefining Cancer Care
2
Disclaimer
This presentation may include predictions, estimates or other information that might be considered forward-looking. While these forward looking statements represent COTI’s current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. COTI has based any forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents COTI has filed with the Toronto Stock Exchange and Ontario Securities Commission. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinion only as of the date of this presentation.
Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of any new information or future events.
3
~ $35B personalized cancer gene profiling market by 2018*
* Markets and Markets (2013) 3
4
Big data problem
How to use information from cancer gene profiling to truly personalize therapy
4
5
Billions
540,000+
1 size
Too many combinations to evaluate?
of mutation profiles
unique single, double & triple drug combos from just 150 drugs
does not fit all!
5
6
Our solution…
Uses gene profile of patient’s tumor to evaluate full range of available therapies
Programmable computer simulation of a human cancer cell
R O S A L I N D R O S A L I N D
7
~100 core processors
10,878* simulations
Results in < 2 hours
* All possible single drugs and 2 drug combinations for 147 drugs
Advantages of ROSALIND
Comprehensiveness and speed
8
Advantages of ROSALIND
Safety: Simulate rather than experiment
Efficiency: Assign patients to most appropriate therapy or clinical trial when predicted optimal therapies are not yet available
9
Our vision
More personalized cancer treatments Higher remission rates + lower cost of cancer therapy
10
Potential revenue models
Patient-based model
Software as a Service
Online service: web portal
11
Patient-based model
0.1% market: $1.6 million
1% market: $16.4 million
5% market: $81.9 million
10% market: $163.9 million
Assumptions: Analysis ordered by attending MD Cost ~$1,000 per patient ~1.6 million new cases annually in US
12
Bronze
Silver
Gold
Platinum
Annual licensing fee
$25,000
$75,000
$150,000
$500,000
Limited users
Limited cases
Medium-sized users
More cases
More users
More features
More cases
Unlimited users
Full features
Unlimited cases
Software as a Service model (SaaS)
13
Online service: web portal
Serves largest population at lowest cost with fastest turn-around and highest security:
– Independently, either in the cloud or on secure servers, and/or
– A version can be offered through an existing online provider (COTI, Google, etc.)
– iTunes type of customizable billing depending on number of drugs/combinations to be evaluated
14
ROSALIND adopted by medical community; demanded by patients
ROSALIND accepted, reimbursed, and ultimately required, by healthcare insurers and payers
Realistic goals
15
Validation – next steps
Database (ROSALIND): 1 patient = 1 gene profile
Obtain patient biopsy at time of diagnosis
Genetic profiling and xenograft (1 xenograft = 1 patient)
Use ROSALIND to predict optimal therapies for genetic profile in question
Use top 2 or 3 predictions for xenograft confirmation
Add to database for future reference
Grow database with global results and translate into personalized treatment options
Phase 1: perhaps 1,000 patients/gene profiles
16
Actual human tumor gene profile
Mutations:
• Oncogenes: EGFR, CCND1
• Tumor suppressor: ARID1A
Example: Actual Commercial Profile
Some common therapies for this profile could include:
Gefitinib
Carboplatin
Paclitaxel (Abraxane)
Gemcitabine
Irinotecan
17
Actual Patient Profile (cont’d)
ROSALIND evaluated just 129 options:
Remission is not possible with any single drug
BUT - remission may be possible with:
Gefitinib or Tarceva or Cetuximab or Panitumumab + Paclitaxel or
Carboplatin + Paclitaxel or
Gemcitabine + Paclitaxel or
Irinotecan + Paclitaxel
There are also several other Paclitaxel based 3 drug combinations that could be considered
18
Thank you
For more information, please contact:
Dr. Wayne R. Danter, President & CEO
Critical Outcome Technologies, Inc. Suite 213, 700 Collip Circle, London, Ontario, Canada N6G 4X8
T: (519) 858-5157 E: [email protected]